Patients with type 2 diabetes mellitus (T2DM) are at high risk for cardiovascular (CV)
disease; however, conclusive evidence that glycemic control leads to improved …

Background The cardiovascular safety and efficacy of many current antihyperglycemic
agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear …

Background It is important to establish the cardiovascular (CV) safety profile of novel
antidiabetic drugs. Methods Pooled analyses were performed of 20 randomized controlled …

Objective: The objective was to assess the relative risk (RR) for cardiovascular (CV) events
across all 8 randomized phase 2/3 trials evaluating saxagliptin in patients with type 2 …

Saxagliptin (Onglyza®) is a highly potent, reversible, competitive dipeptidyl peptidase-4
inhibitor indicated for the treatment of patients with type 2 diabetes. Numerous well …

OBJECTIVES: Saxagliptin, a dipeptidyl peptidase 4 inhibitor, improves glycemic control in
patients with type 2 diabetes mellitus (T2DM) by increasing endogenous active, intact …

Introduction: The worldwide prevalence of type 2 diabetes mellitus (T2DM) is high, and the
chronically poor metabolic control that can result from T2DM is associated with a high risk for …

Background and aims SAVOR‐TIMI 53 was designed to study the effects of the DPP‐4
inhibitor saxagliptin on cardiovascular outcomes in high risk type 2 diabetes patients with …

OBJECTIVE To examine the safety and cardiovascular (CV) effects of saxagliptin in the
predefined elderly (≥ 65 years) and very elderly (≥ 75 years) subpopulations of the …

BACKGROUND: Some conventional therapies for type 2 diabetes mellitus (T2DM) fail to
address the progressive nature of the disease, and as a result, they may become ineffective …